{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:13:50Z","timestamp":1792214030549,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40268-018-0237-9","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T21:44:57Z","timestamp":1529012697000},"page":"191-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Octreotide Use in Neonates: A Case Series"],"prefix":"10.1007","volume":"18","author":[{"given":"Syed Ahmed","family":"Zaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan B.","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"237_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.earlhumdev.2015.04.008","volume":"91","author":"D Testoni","year":"2015","unstructured":"Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH, Smith PB, Best Pharmaceuticals for Children Act-Pediatrics Trial Network Administrative Core Committee. Safety of octreotide in hospitalized infants. Early Hum Dev. 2015;91:387\u201392.","journal-title":"Early Hum Dev."},{"key":"237_CR2","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1111\/j.1651-2227.2011.02529.x","volume":"101","author":"D Shah","year":"2012","unstructured":"Shah D, Sinn JK. Octreotide as a therapeutic option for congenital idiopathic chylothorax: a case series. Acta Paediatr. 2012;101:e151\u20135.","journal-title":"Acta Paediatr."},{"key":"237_CR3","unstructured":"US Food and Drug Administration. Sandostatin (octreotide acetate) injection. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019667s061lbl.pdf\n                    \n                  . Accessed 8 Aug 2017."},{"key":"237_CR4","first-page":"CD006388","volume":"9","author":"A Das","year":"2010","unstructured":"Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. Cochrane Database Syst Rev. 2010;9:CD006388.","journal-title":"Cochrane Database Syst Rev."},{"key":"237_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0218492316682670","volume":"25","author":"AS Aljazairi","year":"2017","unstructured":"Aljazairi AS, Bhuiyan TA, Alwadai AH, Almehizia RA. Octreotide use in post-cardiac surgery chylothorax: a 12\u00a0year perspective. Asian Cardiovasc Thorac Ann. 2017;25:6\u201312.","journal-title":"Asian Cardiovasc Thorac Ann."},{"key":"237_CR6","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.jpedsurg.2013.05.064","volume":"48","author":"MW Landis","year":"2013","unstructured":"Landis MW, Butler D, Lim FY, Keswani S, Frischer J, Haberman B, Kingma PS. Octreotide for chylous effusion in congenital diaphragmatic hernia. J Pediatr Surg. 2013;48:2226\u20139.","journal-title":"J Pediatr Surg."},{"key":"237_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/pds.4144","volume":"26","author":"AW McMohan","year":"2017","unstructured":"McMohan AW, Wharton GT, Thornton P, De Leon DD. Octreotide use and safety in infants with hyperinsulinism. Pharmacoepidemiol Drug Saf. 2017;26:26\u201331.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"237_CR8","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.3748\/wjg.v18.i43.6333","volume":"18","author":"S Al Sinani","year":"2012","unstructured":"Al Sinani S, Rawahi YA, Abdoon H. Octreotide in Hennekam syndrome associated intestinal lymphangiectasia. World J Gastroenetrol. 2012;18:6333\u20137.","journal-title":"World J Gastroenetrol."},{"key":"237_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/jpc.12477","volume":"50","author":"L Downie","year":"2014","unstructured":"Downie L, Sasi A, Malhotra A. Congenital chylothorax: association and neonatal outcomes. J Paediatr Child Health. 2014;50:234\u20138.","journal-title":"J Paediatr Child Health."},{"key":"237_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00383-010-2730-2","volume":"27","author":"J Moreira-Pinto","year":"2011","unstructured":"Moreira-Pinto J, Rocha P, Osorio A, Bonet B, Carvalho F, Duarte C, Oliveira L. Octreotide in the treatment of neonatal postoperative chylothorax: report of three cases and literature review. Pediatr Surg Int. 2011;27:805\u20139.","journal-title":"Pediatr Surg Int."},{"key":"237_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000485184","volume":"89","author":"I Steen Van der","year":"2018","unstructured":"Van der Steen I, van Albada ME, Mohnike K, Christesen HT, Empting S, Salomon-Estebanez M, Greve Rasmussen A, Verrijn Stuart A, van der Linde AAA, Banerjee I, Boot AM. A multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism. Horm Res Paediatr. 2018;89:82\u20139.","journal-title":"Horm Res Paediatr."},{"key":"237_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1634\/theoncologist.2011-0458","volume":"17","author":"L Sid\u00e9ris","year":"2012","unstructured":"Sid\u00e9ris L, Dub\u00e9 P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17:747\u201355.","journal-title":"Oncologist."},{"key":"237_CR13","first-page":"91","volume":"45","author":"C Bellini","year":"2012","unstructured":"Bellini C, Ergaz Z, Radicioni M, Forner-Cordero I, Witte M, Perotti G, et al. Congenital fetal and neonatal visceral chylous effusions: neonatal chylothorax and chylous ascites revisited. A multicentre retrospective study. Lymphology. 2012;45:91\u2013102.","journal-title":"Lymphology."},{"key":"237_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1747-0803.2010.00464.x","volume":"5","author":"L Caverly","year":"2010","unstructured":"Caverly L, Rausch CM, da Cruz E, Kaufman J. Octreotide treatment of chylothorax in pediatric patients following cardiothoracic surgery. Congenit Heart Dis. 2010;5:573\u20138.","journal-title":"Congenit Heart Dis."},{"key":"237_CR15","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jpedsurg.2017.03.010","volume":"52","author":"JT Church","year":"2017","unstructured":"Church JT, Antunez AG, Dean A, Matusko N, Deatrick KB, Attar MA, Gadepalli SK. Evidence based management of chylothorax in infants. J Pediatr Surg. 2017;52:907\u201312.","journal-title":"J Pediatr Surg."},{"key":"237_CR16","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1016\/S0022-3468(03)00294-X","volume":"38","author":"A Goyal","year":"2003","unstructured":"Goyal A, Smith NP, Jesudason EC, Kerr S, Losty PD. Octreotide for treatment of chylothorax after repair of congenital diaphragmatic hernia. J Pediatr Surg. 2003;38:E19\u201320.","journal-title":"J Pediatr Surg."},{"key":"237_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/2249-4847.96767","volume":"1","author":"RA Jarir","year":"2012","unstructured":"Jarir RA, Rahman SU, Bassiounylel S. Use of octreotide in the management of neonatal chylothorax secondary to repair of congenital diaphragmatic hernia: a report of two cases and review of literature. J Clin Neonatol. 2012;1:91\u20135.","journal-title":"J Clin Neonatol."},{"key":"237_CR18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jpedsurg.2005.12.041","volume":"41","author":"A Paget-Brown","year":"2006","unstructured":"Paget-Brown A, Kattwinkel J, Rodgers BM, Micchalsky MP. The use of octreotide to treat congenital chylothorax. J Pediatr Surg. 2006;41:854\u20137.","journal-title":"J Pediatr Surg."},{"key":"237_CR19","doi-asserted-by":"publisher","first-page":"e7594","DOI":"10.1097\/MD.0000000000007594","volume":"96","author":"R Yin","year":"2017","unstructured":"Yin R, Zhang R, Wang J, Yuan L, Hu L, Jiang S, Chen C, Cao Y. Effects of somatostatin\/octreotide treatment in neonates with congenital chylothorax. Medicine (Baltim). 2017;96:e7594.","journal-title":"Medicine (Baltim)."},{"key":"237_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/sj.jp.7211053","volume":"24","author":"S Young","year":"2004","unstructured":"Young S, Dalgleish S, Eccleston A, Akierman A, McMillan D. Severe congenital chylothorax treated with octreotide. J Perinatol. 2004;24:200\u20132.","journal-title":"J Perinatol."},{"key":"237_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/j.1552-4604.1995.tb04746.x","volume":"35","author":"AG Harris","year":"1995","unstructured":"Harris AG, Kokoris SP, Ezzat S. Continous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. J Clin Pharmacol. 1995;35:59\u201371.","journal-title":"J Clin Pharmacol."},{"key":"237_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.beem.2009.08.003","volume":"23","author":"BR Haugen","year":"2009","unstructured":"Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23:793\u2013800.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"237_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Roberts I, Ruiz A, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther."},{"key":"237_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/jpsu.2003.50056","volume":"38","author":"RP Arevalo","year":"2003","unstructured":"Arevalo RP, Bullabh P, Krauss AN, Auld PA, Spigland N. Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates. J Pediatr Surg. 2003;38:251\u20133.","journal-title":"J Pediatr Surg."},{"key":"237_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.13889","author":"C Bellini","year":"2018","unstructured":"Bellini C, Cabano R, De Angelis LC, Bellini T, Calevo MG, Gandullia P, Ramenghi LA. Octreotide for congenital and acquired chylothorax in newborns: a systematic review. J Paediatr Child Health. 2018. \n                    https:\/\/doi.org\/10.1111\/jpc.13889\n                    \n                   (Epub ahead of print).","journal-title":"J Paediatr Child Health."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0237-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T19:18:34Z","timestamp":1560539914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0237-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["237"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0237-9","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]},"assertion":[{"value":"15 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Syed Ahmed Zaki, Mohan B. Krishnamurthy and Atul Malhotra have no conflicts of interest directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"SAZ collected and analysed the data and wrote the first draft of the\u00a0manuscript. MBK reviewed the manuscript. AM conceived the study idea,\u00a0supervised the writing of the manuscript and critically revised the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}},{"value":"The study was approved by the Monash Health Human Research Ethics Committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}